95 related articles for article (PubMed ID: 20493474)
1. Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women.
Karaflou M; Kaparos G; Rizos D; Creatsa M; Christodoulakos G; Lambrinoudaki I
Fertil Steril; 2010 Nov; 94(6):2399-401. PubMed ID: 20493474
[TBL] [Abstract][Full Text] [Related]
2. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
3. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
[TBL] [Abstract][Full Text] [Related]
4. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
[TBL] [Abstract][Full Text] [Related]
5. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
Ylikorkala O; Lim P; Caubel P
Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
[TBL] [Abstract][Full Text] [Related]
6. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
7. Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.
Lambrinoudaki IV; Christodoulakos GE; Economou EV; Vlachou SA; Panoulis CP; Alexandrou AP; Kouskouni EE; Creatsas GC
Maturitas; 2008 Jan; 59(1):62-71. PubMed ID: 18164562
[TBL] [Abstract][Full Text] [Related]
8. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
Junge W; El-Samalouti V; Gerlinger C; Schaefers M
Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
[TBL] [Abstract][Full Text] [Related]
9. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
[TBL] [Abstract][Full Text] [Related]
10. Progestin may modify the effect of low-dose hormone therapy on mammographic breast density.
Panoulis C; Lambrinoudaki I; Vourtsi A; Augoulea A; Kaparos G; Aravantinos L; Christodoulakos G; Creatsas G
Climacteric; 2009 Jun; 12(3):240-7. PubMed ID: 19387881
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and metabolic effects of estrogen plus progestin therapy in hypertensive postmenopausal women treated with an ACE-inhibitor or a diuretic.
Posadzy-Malaczynska A; Rajpold K; Woznicka-Leskiewicz L; Marcinkowska J
Clin Res Cardiol; 2015 Jan; 104(1):38-50. PubMed ID: 25216597
[TBL] [Abstract][Full Text] [Related]
12. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
Christodoulakos GE; Lambrinoudaki IV; Creatsa MG; Economou EV; Siasou Z; Panoulis CP; Kalligerou I; Papadias C
Climacteric; 2008 Apr; 11(2):155-65. PubMed ID: 18365858
[TBL] [Abstract][Full Text] [Related]
13. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
Davis SR; Stuckey BG; Norman RJ; Papalia MA; Drillich A; Bell RJ
Menopause; 2008; 15(6):1065-9. PubMed ID: 18806686
[TBL] [Abstract][Full Text] [Related]
14. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the central effects of different progestins used in hormone replacement therapy.
Cagnacci A; Arangino S; Baldassari F; Alessandrini C; Landi S; Volpe A
Maturitas; 2004 Aug; 48(4):456-62. PubMed ID: 15283939
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women.
Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA
J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162
[TBL] [Abstract][Full Text] [Related]
17. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
[TBL] [Abstract][Full Text] [Related]
18. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
Archer DF; Thorneycroft IH; Foegh M; Hanes V; Glant MD; Bitterman P; Kempson RL
Menopause; 2005; 12(6):716-27. PubMed ID: 16278615
[TBL] [Abstract][Full Text] [Related]
20. Drospirenone and estradiol: a new option for the postmenopausal woman.
Archer DF
Climacteric; 2007 Feb; 10 Suppl 1():3-10. PubMed ID: 17364592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
